Search

Your search keyword '"Leto, Gaetano"' showing total 272 results
Start Over Author "Leto, Gaetano"
272 results on '"Leto, Gaetano"'

2. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk

Author

Baldassarre, Mariella, Consoli, Agostino, Morganet, Sara, Zugaro, Antonella, Baroni, Marco Giorgio, Andreozzi, Francesco, Gatti, Adriano, De Riu, Stefano, Del Buono, Andrea, Aldigeri, Raffaella, Bonadonna, Riccardo, Cas, Alessandra Dei, Vazzana, Angela, Antonini, Monica, Moretti, Valentina, Volsi, Patrizia Li, Cesare, Miranda, Zanette, Giorgio, Carletti, Silvia, D'Angelo, Paola, Leto, Gaetano, Leonetti, Frida, D'Onofrio, Luca, Maddaloni, Ernesto, Buzzetti, Raffaella, Frontoni, Simona, Cavallo, Giselle, Morano, Susanna, Filardi, Tiziana, Capece, Umberto, Giaccari, Andrea, Bossi, Antonio C., Meregalli, Giancarla, Querci, Fabrizio, Gaglio, Alessia, Resi, Veronica, Orsi, Emanuela, Fazion, Stefano, Franzetti, Ivano G., Berra, Cesare, Manfrini, Silvia, Garrapa, Gabriella, Lucarelli, Giulio, Riccialdelli, Lara, Tortato, Elena, Zavattaro, Marco, Aimaretti, Gianluca, Cavalot, Franco, Beccuti, Guglielmo, Broglio, Fabio, Fattor, Bruno, Cazzetta, Giuliana, Lamacchia, Olga, Rauseo, Anna, De Cosmo, Salvatore, Cau, Rosella, Ghiani, Mariangela, Di Benedetto, Antonino, Di Pino, Antonino, Piro, Salvatore, Purrello, Francesco, Frittitta, Lucia, Milluzzo, Agostino, Russo, Giuseppina, Fadini, Gian Paolo, Longato, Enrico, Morieri, Mario Luca, Del Prato, Stefano, Avogaro, Angelo, and Solini, Anna

Published
2024
Full Text
View/download PDF

7. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk

Author

Fadini, Gian Paolo, primary, Longato, Enrico, additional, Morieri, Mario Luca, additional, Del Prato, Stefano, additional, Avogaro, Angelo, additional, Solini, Anna, additional, Baldassarre, Mariella, additional, Consoli, Agostino, additional, Morganet, Sara, additional, Zugaro, Antonella, additional, Baroni, Marco Giorgio, additional, Andreozzi, Francesco, additional, Gatti, Adriano, additional, De Riu, Stefano, additional, Del Buono, Andrea, additional, Aldigeri, Raffaella, additional, Bonadonna, Riccardo, additional, Cas, Alessandra Dei, additional, Vazzana, Angela, additional, Antonini, Monica, additional, Moretti, Valentina, additional, Volsi, Patrizia Li, additional, Cesare, Miranda, additional, Zanette, Giorgio, additional, Carletti, Silvia, additional, D'Angelo, Paola, additional, Leto, Gaetano, additional, Leonetti, Frida, additional, D'Onofrio, Luca, additional, Maddaloni, Ernesto, additional, Buzzetti, Raffaella, additional, Frontoni, Simona, additional, Cavallo, Giselle, additional, Morano, Susanna, additional, Filardi, Tiziana, additional, Capece, Umberto, additional, Giaccari, Andrea, additional, Bossi, Antonio C., additional, Meregalli, Giancarla, additional, Querci, Fabrizio, additional, Gaglio, Alessia, additional, Resi, Veronica, additional, Orsi, Emanuela, additional, Fazion, Stefano, additional, Franzetti, Ivano G., additional, Berra, Cesare, additional, Manfrini, Silvia, additional, Garrapa, Gabriella, additional, Lucarelli, Giulio, additional, Riccialdelli, Lara, additional, Tortato, Elena, additional, Zavattaro, Marco, additional, Aimaretti, Gianluca, additional, Cavalot, Franco, additional, Beccuti, Guglielmo, additional, Broglio, Fabio, additional, Fattor, Bruno, additional, Cazzetta, Giuliana, additional, Lamacchia, Olga, additional, Rauseo, Anna, additional, De Cosmo, Salvatore, additional, Cau, Rosella, additional, Ghiani, Mariangela, additional, Di Benedetto, Antonino, additional, Di Pino, Antonino, additional, Piro, Salvatore, additional, Purrello, Francesco, additional, Frittitta, Lucia, additional, Milluzzo, Agostino, additional, and Russo, Giuseppina, additional

Published
2024
Full Text
View/download PDF

8. Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.

Author

Fadini, Gian Paolo, Bonora, Benedetta Maria, Ghiani, Mariangela, Anichini, Roberto, Melchionda, Elena, Fattor, Bruno, Fazion, Stefano, Meregalli, Giancarla, Giaccari, Andrea, Avogaro, Angelo, Consoli, Agostino, Baldassarre, Maria Antonia Pompea, Formoso, Gloria, Leto, Gaetano, Leonetti, Frida, Zavattaro, Marco, Aimaretti, Gianluca, Barale, Cristina, Cau, Rosella, and Muscarà, Andrea

Subjects
TYPE 2 diabetes, SEMAGLUTIDE, GLUCAGON-like peptide-1 receptor, GLUCAGON-like peptide-1 agonists, BODY mass index
Abstract

Aim: To investigate the real‐world utilization and comparative clinical outcomes of injectable and oral semaglutide in individuals with type 2 diabetes (T2D) with the aim of enhancing understanding of the practical implications associated with choosing between these formulations. Methods: New users of oral or injectable semaglutide were selected from a cohort of 14 079 initiators of glucagon‐like peptide‐1 receptor agonists. Propensity‐score matching (PSM) was employed to create balanced groups, ensuring comparability. The analysis encompassed dose exposure, drug persistence, and clinical outcomes, including changes in glycated haemoglobin (HbA1c) and body weight, with up to 18 months' follow‐up. Results: We analysed two matched groups of 107 participants each, who comprised on average 63.6% men, aged 64 years, with diabetes duration of approximately 10 years, body mass index of 29 kg/m2 and HbA1c level of 7.7–7.8% (61‐62 mmol/mol). The proportion of low, intermediate and high doses were similar with the oral and the injectable formulation. The change in HbA1c was similar between groups (−0.9% / ‐10 mmol/mol at 18 months) as was the proportion of individuals reaching HbA1c <6.5% (48 mmol/mol). The average change in body weight was similar in the two groups (−3.7 kg with injectable and −3.3 kg with oral at 18 months) but more new users of injectable semaglutide lost ≥5% body weight. Persistence on drug was longer with injectable than with oral semaglutide. Conclusion: In a real‐world setting, improvements in HbA1c and body weight were similar after initiation of oral or injectable semaglutide. These results may be specific to the features of the matched cohorts under investigation, with limited generalizability to populations with different characteristics. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Author

Vaccaro, Olga, Masulli, Maria, Nicolucci, Antonio, Maggioni, Aldo Pietro, Sesti, Giorgio, Mocarelli, Paolo, Lucisano, Giuseppe, Sacco, Michele, Signorini, Stefano, Cappellini, Fabrizio, Riccardi, Gabriele, Boemi, Massimo, D'Angelo, Federica, Giansanti, Roberto, Tanase, Laura, Lanari, Luigi, Testa, Ivano, Ricci, Lucia, Pancani, Francesca, Ranchelli, Anna, Vagheggi, Paolo, Scatona, Alessia, Fontana, Lucia, Giorgino, Francesco, Laviola, Luigi, Tarantino, Lucia, Ippolito, Claudia, Gigantelli, Vittoria, Manicone, Mariangela, Conte, Eleonora, Trevisan, Roberto, Scaranna, Cristiana, Rota, Rossella, Corsi, Anna, Dodesini, Alessandro R., Reggiani, Giulio Marchesini, Montesi, Luca, Mazzella, Natalia, Forlani, Gabriele, Caselli, Chiara, Di Luzio, Raffaella, Mazzotti, Arianna, Aiello, Antimo, Barrea, Angelina, Musto, Antonio, D'Amico, Fiorentina, Squatrito, Sebastiano, Sinagra, Tiziana, Longhitano, Sara, Trowpea, Vanessa, Sparti, Maria, Italia, Salvatore, Lisi, Enrico, Grasso, Giuseppe, Pezzino, Vincenzo, Insalaco, Federica, Gnasso, Agostino, Carallo, Claudio, Scicchitano, Caterina, De Franceschi, Maria Serena, Santini, Costanza, Calbucci, Giovanni, Ripani, Raffaella, Corsi, Laura, Cuneo, Giacomo, Corsi, Simona, Giorda, Carlo B., Romeo, Francesco, Lesina, Annalisa, Comoglio, Marco, Bonetto, Caterina, Robusto, Anna, Nada, Elisa, Asprino, Vincenzo, Cetraro, Rosa, Impieri, Michelina, Lucchese, Giuseppe, Donnarumma, Giovanna, Tizio, Biagio, Clemente, Gennaro, Lenza, Lazzaro, Paraggio, Pia, Tomasi, Franco, Zamboni, Chiara, Dozio, Nicoletta, Scalambra, Egle, Mannucci, Edoardo, Lamanna, Caterina, Cignarelli, Mauro, Macchia, Olga La, Fariello, Stefania, Sorrentino, Maria Rosaria, Franzetti, Ivano, Radin, Raffaella, Cordera, Renzo, Annunziata, Francesca, Bonabello, Laura Affinito, Durante, Arianna, Dolcino, Mara, Gallo, Fiorenza, Mazzucchelli, Chiara, Aleo, Anna, Melga, Pierluigi, Briatore, Lucia, Maggi, Davide, Storace, Daniela, Cecoli, Francesca, Antenucci, Daniela, D'Ugo, Ercole, Pupillo, Mario, Baldassarre, Maria Pompea Antonia, Salvati, Filippo, Minnucci, Anita, De Luca, Angelo, Zugaro, Antonella, Santarelli, Livia, Bosco, Angela, Petrella, Vittorio, La Verghetta, Grazia Giovanna, Iannarelli, Rossella, De Gregorio, Antonella, D'Andrea, Settimio, Giuliani, Anna Elisa, Polidoro, w Lorella, Sperandio, Alessandra, Sciarretta, Filomena, Pezzella, Alfonso, Buzzetti, Raffaella, Carlone, Angela, Potenziani, Stella, Venditti, Chiara, Foffi, Chiara, Carbone, Salvatore, Cipolloni, Laura, Moretti, Chiara, Leto, Gaetano, Serra, Rosalia, Petrachi, Francesca, Romano, Isabella, Di Cianni, Graziano, Lacaria, Emilia, Russo, Laura, Goretti, Chiara, Sannino, Claudia, Gregori, Giovanna, Dolci, Maria, Bruselli, Laura, Mori, Mary L., Baccetti, Fabio, Del Freo, Maria, Di Benedetto, Antonino, Cucinotta, Domenico, Giunta, Loretta, Ruffo, Maria Concetta, Cannizzaro, Desiree, Pintaudi, Basilio, Perrone, Giovanni, Pata, Pietro, Ragonese, Francesco, Lettina, Gabriele, Mancuso, Teresa, Coppolino, Aldo, Piatti, Pier Marco, Monti, Lucilla, Stuccillo, Michela, Lucotti, Pietro, Setola, Manuela, Crippa, Giulia Valentina, Loi, Cinzia, Oldani, Matteo, Bottalico, Maria Luisa, Pellegata, Beatrice, Bonomo, Matteo, Menicatti, Laura Silvia Maria, Resi, Veronica, Bertuzzi, Federico, Disoteo, Eugenia Olga, Pizzi, Gianluigi, Rivellese, Angela Albarosa, Annuzzi, Giovanni, Capaldo, Brunella, Nappo, Rossella, Auciello, Stefania Michela, Turco, Anna Amelia, Costagliola, Lucia, Iovine, Ciro, Corte, Giuseppina Della, Vallefuoco, Pasquale, Nappi, Francesca, Vitale, Marilena, Cocozza, Sara, Ciano, Ornella, Massimino, Elena, Garofalo, Nadia, Avogaro, Angelo, Vedovato, Monica, Guarneri, Gabriella, Lapolla, Annunziata, Fedele, Domenico, Sartore, Giovanni, Chilelli, Nino Cristiano, Burlina, Silvia, Bonsembiante, Barbara, Giordano, Carla, Galluzzo, Aldo, Torregrossa, Vittoria, Dall'Aglio, Elisabetta, Mancastroppa, Giovanni, Arsenio, Leone, Cioni, Federico, Caronna, Silvana, Papi, Matteo, Babini, Massimiliano, Perriello, Gabriele, Santeusanio, Fausto, Calagreti, Gioia, Timi, Alessia, Tantucci, Alice, Marino, Cecilia, Consoli, Agostino, Ginestra, Federica, Di Biagio, Rosamaria, Taraborelli, Merilda, Del Prato, Stefano, Miccoli, Roberto, Bianchi, Cristina, Garofolo, Monia, Politi, Konstantina Savina, Penno, Giuseppe, Zavaroni, Donatella, Livraga, Stefania, Calzoni, Fabio, Mancastroppa, Giovanni Luigi Francesco, Anichini, Roberto, Corsini, Elisa, Tedeschi, Anna, Gaglianò, Maria Sole, Ippolito, Giulio, Salutini, Elisabetta, Citro, Giuseppe, Cervellino, Francesco, Natale, Maria, Salvatore, Vita, Zampino, Armando, Sinisi, Rosa, Calabrese, Maria, Arcangeli, Adolfo, Zogheri, Alessia, Guizzotti, Sandra, Longo, Rossella, Di Bartolo, Paolo, Pellicano, Francesca, Scolozzi, Patrizia, Termine, Simona, Luberto, Alessandra, Ballardini, Giorgio, Babini, Anna Carla, Trojani, Cristina, Mazzuca, Paolo, Bruglia, Matteo, Ciamei, Monica, Genghini, Silvia, Zannoni, Chiara, Pugliese, Giuseppe, Vitale, Martina, Rangel, Graziela, Salvi, Laura, Zappaterreno, Alessandra, Cordone, Samantha, Simonelli, Paola, Meggiorini, Marilla, Frasheri, Aurora, Di Pippo, Clelia, Maglio, Cristina, Mazzitelli, Giulia, Lauro, Davide, Rinaldi, Maria Elena, Galli, Angelica, Romano, Maria, D'Angelo, Paola, Leotta, Sergio, Suraci, Concetta, De Cosmo, Salvatore, Bacci, Simonetta, Palena, Antonio Pio, Genovese, Stefano, Mancino, Monica, Rondinelli, Maurizio, Capone, Filippo, Calabretto, Elisabetta, Bulgheroni, Monica, Bucciarelli, Loredana, Dotta, Francesco, Ceccarelli, Elena, Fondelli, Cecilia, Santacroce, Clorinda, Guarino, Elisa, Nigi, Laura, Lalli, Carlo, Di Vizia, Giovanni, Scarponi, Maura, Montani, Valeria, Di Bernardino, Paolo, Romagni, Paola, Dolcetti, Katia, Cannarsa, Emanuela, Forte, Elisa, Tamburo, Lucilla, Fornengo, Paolo, Perin, Paolo Cavallo, Prinzis, Tania, Gruden, Gabriella, Bruno, Graziella, Zucco, Chiara, Perotta, Massimo, Marena, Saverio, Monsignore, Simona, Panero, Francesco, Ponzi, Fulvia, Bossi, Antonio Carlo, Carpinteri, Rita, Casagrande, Maria Linda, Coletti, Maria Francesca, Balini, Annalisa, Filopanti, Marcello, Madaschi, Sara, Pulcina, Anna, Grimaldi, Franco, Tonutti, Laura, Venturini, Giorgio, Agus, Sandra, Pagnutti, Stefania, Guidotti, Francesca, Cavarape, Alessandro, Bonora, Enzo, Cigolini, Massimo, Pichiri, Isabella, Brangani, Corinna, Fainelli, Giulia, Tomasetto, Elena, Zoppini, Giacomo, Galletti, Anna, Perrone, Dominica, Capra, Claudio, Bianchini, Francesca, Ceseri, Martina, Di Nardo, Barbara, Sasso, Elisa, Bartolomei, Barbara, Suliman, Irina, Fabbri, Gianna, Romano, Geremia, Maturo, Nicola, Nunziata, Giuseppe, Capobianco, Giuseppe, De Simone, Giuseppina, Villa, Valeria, Rota, Giuseppe, Pentangelo, Carmine, Carbonara, Ornella, Caiazzo, Gennaro, Cutolo, Michele, Sorrentino, Tommasina, Mastrilli, Valeria, Amelia, Umberto, Masi, Stefano, Corigliano, Gerardo, Gaeta, Iole, Armentano, Vincenzo, Calatola, Pasqualino, Capuano, Gelsomina, Angiulli, Bruno, Auletta, Pasquale, Petraroli, Ettore, Iodice, Cinzia E., Agrusta, Mariano, Maggioni, Aldo P, Rivellese, Angela A, Giorda, Carlo B, La Macchia, Olga, Bossi, Antonio C, and di Bartolo, Paolo

Published
2017
Full Text
View/download PDF

13. Prevalence and risk factors of glomerular hyperfiltration in adults with type 2 diabetes: A population‐based study.

Author

Tricò, Domenico, Fadini, Gian Paolo, Morieri, Mario Luca, Candido, Riccardo, Disoteo, Olga Eugenia, Frontoni, Simona, Solini, Anna, Caprio, Massimiliano, Formoso, Gloria, Forte, Elisa, Frison, Vera, Gregori, Giovanna, Lencioni, Cristina, Leto, Gaetano, Marangoni, Alberto, Negri, Carlo, Nollino, Laura, Perrelli, Andrea, Prodam, Flavia, and Rebora, Alberto

Subjects
DIABETIC nephropathies, TYPE 2 diabetes, LDL cholesterol, ADULTS, ELECTRONIC health records, GLOMERULAR filtration rate
Abstract

Aims: Glomerular hyperfiltration characterises the earliest stage of diabetic nephropathy and predicts adverse kidney and cardiovascular outcomes. We aimed to assess the prevalence and risk factors of glomerular hyperfiltration in a population‐based contemporary cohort of individuals with type 2 diabetes (T2D). Materials and Methods: The prevalence of unequivocal glomerular hyperfiltration (defined by an estimated glomerular filtration rate >120 mL/min/1.73 m2) and its associated risk factors were identified in a cohort of 202,068 adult patients with T2D receiving specialist care in 2021–2022, whose center‐aggregated data were automatically extracted from electronic medical records of 75 diabetes clinics in Italy. Results: Glomerular hyperfiltration was identified in 1262 (0.6%) participants. The prevalence of glomerular hyperfiltration varied widely across centers (0%–3.4%) and correlated with mean center age, HbA1c, body mass index (BMI), and low‐density lipoprotein cholesterol. Patients in centers with high glomerular hyperfiltration prevalence (>0.8%) were more often men and had lower age and BMI, but more frequent albuminuria and worse glucose, lipid, and blood pressure control, compared with low‐normal prevalence centers. Conclusions: Unequivocal glomerular hyperfiltration can be identified in up to 3.4% of patients receiving up‐to‐date specialist diabetes care. Glomerular hyperfiltration prevalence varies across centers and substantially increases with suboptimal control of metabolic risk factors, which would require improved management to mitigate the negative health consequences of this pathological condition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care.

Author

Morieri, Mario Luca, Candido, Riccardo, Frontoni, Simona, Disoteo, Olga, Solini, Anna, Fadini, Gian Paolo, Bellanti, Francesco, Caprio, Massimiliano, Cutolo, Michele, Formoso, Gloria, Forte, Elisa, Frison, Vera, Gregori, Giovanna, Lencioni, Cristina, Leto, Gaetano, Mandica, Salvatore, Marangoni, Alberto, Memoli, Pasqualina, Memoli, Giuseppe, and Negri, Carlo

Subjects
TYPE 2 diabetes, CARDIOVASCULAR diseases risk factors, SEMAGLUTIDE, GLYCEMIC control, NURSE practitioners, DISEASE duration
Abstract

Introduction: This study aimed to address therapeutic inertia in the management of type 2 diabetes (T2D) by investigating the potential of early treatment with oral semaglutide. Methods: A cross-sectional survey was conducted between October 2021 and April 2022 among specialists treating individuals with T2D. A scientific committee designed a data collection form covering demographics, cardiovascular risk, glucose control metrics, ongoing therapies, and physician judgments on treatment appropriateness. Participants completed anonymous patient questionnaires reflecting routine clinical encounters. The preferred therapeutic regimen for each patient was also identified. Results: The analysis was conducted on 4449 patients initiating oral semaglutide. The population had a relatively short disease duration (42% < 5 years), and a minority (15.6%) had a history of cardiovascular events. Importantly, oral semaglutide was started in subjects with various disease durations and background therapies. Notably, its initiation was accompanied by de-prescription of sulfonylureas, pioglitazone, DPP-4 inhibitors, and insulin. Choice of oral semaglutide was influenced by patient profiles and ongoing glucose-lowering regimens. Factors such as younger age, higher HbA1c, and ongoing SGLT-2 inhibitor therapy drove the choice of oral semaglutide with the aim of improving glycemic control. Projected glycemic effectiveness analysis revealed that oral semaglutide could potentially lead HbA1c to target in > 60% of patients, and more often than sitagliptin or empagliflozin. Conclusion: The study supports the potential of early implementation of oral semaglutide as a strategy to overcome therapeutic inertia and enhance T2D management. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Lack of Association between Serum Chitotriosidase Activity and Arterial Stiffness in Type 2 Diabetes without Cardiovascular Complications.

Author

D'Onofrio, Luca, Amendolara, Rocco, Mignogna, Carmen, Leto, Gaetano, Tartaglione, Lida, Mazzaferro, Sandro, Maddaloni, Ernesto, and Buzzetti, Raffaella

Subjects
ARTERIAL diseases, TYPE 2 diabetes, CARDIOLOGICAL manifestations of general diseases, PULSE wave analysis, DIASTOLIC blood pressure
Abstract

Chitotriosidase (CHIT), a mammalian chitinase secreted by neutrophils and activated macrophages, is increased in both cardiovascular disease (CVD) and type 2 diabetes (T2D). Arterial stiffness rises early in T2D and increases the risk of CVD. The aim of this study is to evaluate CHIT activity as an early biomarker of arterial stiffness in people with T2D free from overt vascular complications. In this cross-sectional study, arterial stiffness as measured using standard pulse wave velocity (PWV) was evaluated in 174 people with T2D without overt vascular disease. Then, we measured CHIT serum activity with an electrochemiluminescence assay in two subgroups of participants: 35 with the highest (high-PWV) and 40 with the lowest (low-PWV) PWV values. CHIT activity was no different between the low-PVW and high-PWV groups (12.7 [9.6–17.9] vs. 11.4 [8.8–15.0] nmol/mL/h, respectively). Compared with the low-PWV group, the high-PWV participants were older (p < 0.001); had a longer duration of diabetes (p = 0.03); higher ankle–brachial index ABI (p = 0.04), systolic blood pressure (p = 0.002), diastolic blood pressure (p = 0.005), fasting blood glucose (p = 0.008), and HbA1c (p = 0.005); and lower eGFR (p = 0.03) and body mass index (BMI) (p = 0.01). No association was present with sex, duration of diabetes, age, BMI, peripheral blood pressure, laboratory parameters, and glucose-lowering medications or ongoing antihypertensive therapy. Although no association was found, this study provides novel data about the association of CHIT activity with CVD, focusing on a specific outcome (arterial stiffness) in a well-defined population of subjects with T2D without established CVD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Development of a clinical risk score to predict death in patients with COVID‐19

Author

Alhamar, Ghadeer, primary, Maddaloni, Ernesto, additional, Al Shukry, Abdullah, additional, Al‐Sabah, Salman, additional, Al‐Haddad, Mohannad, additional, Al‐Youha, Sarah, additional, Jamal, Mohammed, additional, Almazeedi, Sulaiman, additional, Al‐Shammari, Abdullah A., additional, Abu‐Farha, Mohamed, additional, Abubaker, Jehad, additional, Alattar, Abdulnabi T., additional, AlOzairi, Ebaa, additional, Alessandri, Francesco, additional, D’Onofrio, Luca, additional, Leto, Gaetano, additional, Mastroianni, Carlo Maria, additional, Mignogna, Carmen, additional, Pascarella, Giuseppe, additional, Pugliese, Francesco, additional, Ali, Hamad, additional, Al Mulla, Fahd, additional, Buzzetti, Raffaella, additional, and Pozzilli, Paolo, additional

Published
2022
Full Text
View/download PDF

28. Effects of the COVID ‐19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study

Author

D'Onofrio, Luca, primary, Pieralice, Silvia, additional, Maddaloni, Ernesto, additional, Mignogna, Carmen, additional, Sterpetti, Sara, additional, Coraggio, Lucia, additional, Luordi, Cecilia, additional, Guarisco, Gloria, additional, Leto, Gaetano, additional, Leonetti, Frida, additional, Manfrini, Silvia, additional, and Buzzetti, Raffaella, additional

Published
2021
Full Text
View/download PDF

32. Adipokines in obesity and metabolic diseases

Author

Giammanco, Marco, primary, Marini, Herbert R., additional, Pallio, Socrate, additional, Giammanco, Manfredi Marco, additional, Tomasello, Giovanni, additional, Carini, Francesco, additional, Venturella, Fabio, additional, Leto, Gaetano, additional, and La Guardia, Maurizio, additional

Published
2021
Full Text
View/download PDF

37. Additional file 1 of Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)

Author

Maddaloni, Ernesto, D’Onofrio, Luca, Alessandri, Francesco, Mignogna, Carmen, Leto, Gaetano, Pascarella, Giuseppe, Mezzaroma, Ivano, Lichtner, Miriam, Pozzilli, Paolo, Agrò, Felice Eugenio, Rocco, Monica, Pugliese, Francesco, Lenzi, Andrea, Rury R. Holman, Mastroianni, Claudio Maria, and Buzzetti, Raffaella

Abstract

Additional file 1:Table S1. SARS-CoV-2 infection symptoms at hospitalization in patients with, compared with those without, diabetes and in patients experiencing the primary composite compared with those without. Table S2. Odds ratio (OR) with [95% confidence intervals, CI] for secondary outcomes, unadjusted and adjusted for age and sex. Abbreviations: CV, cardiovascular; COPD, chronic obstructive pulmonary disease.

Published
2020
Full Text
View/download PDF

45. 441-P: Chitotriosidase Activity Is Inversely Associated with Diastolic Blood Pressure and HbA1c but Not with Arterial Stiffness in Patients with Type 2 Diabetes without Complications

Author

D'ONOFRIO, LUCA, primary, LUORDI, CECILIA, additional, MIGNOGNA, CARMEN, additional, CARLONE, ANGELA, additional, MORETTI, CHIARA, additional, TARTAGLIONE, LIDA, additional, MADDALONI, ERNESTO, additional, LETO, GAETANO, additional, MAZZAFERRO, SANDRO, additional, and BUZZETTI, RAFFAELLA, additional

Published
2019
Full Text
View/download PDF

46. Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes.

Author

Sciannameo, V., Berchialla, P., Avogaro, A., Fadini, G. P., DARWIN-T2D Network, Consoli, Agostino, Formoso, Gloria, Grossi, Giovanni, Pucci, Achiropita, Sesti, Giorgio, Andreozzi, Francesco, Capobianco, Giuseppe, Gatti, Adriano, Bonadonna, Riccardo, Zavaroni, Ivana, DeiCas, Alessandra, Felace, Giuseppe, Li Volsi, Patrizia, Buzzetti, Raffaella, and Leto, Gaetano

Subjects
TYPE 2 diabetes, DISEASE prevalence, CARDIOVASCULAR diseases
Abstract

Background: Transferring results obtained in cardiovascular outcome trials (CVOTs) to the real-world setting is challenging. We herein transposed CVOT results to the population of patients with type 2 diabetes (T2D) seen in routine clinical practice and who may receive the medications tested in CVOTs. Methods: We implemented the post-stratification approach based on aggregate data of CVOTs and individual data of a target population of diabetic outpatients. We used stratum-specific estimates available from CVOTs to calculate expected effect size for the target population by weighting the average of the stratum-specific treatment effects according to proportions of a given characteristic in the target population. Data are presented as hazard ratio (HR) and 95% confidence intervals. Results: Compared to the target population (n = 139,708), the CVOT population (n = 95,816) was younger and had a two to threefold greater prevalence of cardiovascular disease. EMPA-REG was the CVOT with the largest variety of details on stratum-specific effects, followed by TECOS, whereas DECLARE and PIONEER-6 had more limited stratum-specific information. The post-stratification HR estimate for 3 point major adverse cardiovascular event (MACE) based on EMPA-REG was 0.88 (0.74–1.03) in the target population, compared to 0.86 (0.74–0.99) in the trial. The HR estimate based on LEADER was 0.88 (0.77–0.99) in the target population compared to 0.87 (0.78–0.97) in the trial. Consistent results were obtained for SUSTAIN-6, EXSCEL, PIONEER-6 and DECLARE. The effect of DPP-4 inhibitors observed in CVOTs remained neutral in the target population. Conclusions: Based on CVOT stratum-specific effects, cardiovascular protective actions of glucose lowering medications tested in CVOTs are transferrable to a much different real-world population of patients with T2D. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer: relationship with clinicopathologic parameters and prognostic significance

Author

Russo, Antonio, Bazan, Viviana, Gebbia, Nicola, Pizzolanti, Giuseppe, Tumminello, Francesca Maria, Dardanoni, Gabriella, Ingria, Federico, Restivo, Salvatore, Tomasino, Rosa Maria, and Leto, Gaetano

Subjects
Squamous cell carcinoma -- Prognosis, Laryngeal cancer -- Prognosis, Flow cytometry -- Diagnostic use, Health
Published
1995

49. Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study

Author

Fadini, G. P., Solini, A., Manca, M. L., Zatti, G., Karamouzis, I., Di Benedetto, A., Frittitta, L., Avogaro, A., Consoli, Agostino, Formoso, Gloria, Grossi, Giovanni, Pucci, Achiropita, Sesti, Giorgio, Andreozzi, Francesco, Capobianco, Giuseppe, Gatti, Adriano, Bonadonna, Riccardo, Zavaroni, Ivana, Dei Cas, Alessandra, Felace, Giuseppe, Li Volsi, Patrizia, Buzzetti, Raffaella, Leto, Gaetano, Sorice, Gian Pio, D’Angelo, Paola, Morano, Susanna, Bossi, Antonio Carlo, Duratorre, Edoardo, Franzetti, Ivano, Morpurgo, Paola Silvia, Orsi, Emanuela, Querci, Fabrizio, Boemi, Massimo, D’Angelo, Federica, Petrelli, Massimiliano, Aimaretti, Gianluca, Karamouzis, Ioannis, Cavalot, Franco, Saglietti, Giuseppe, Cazzetta, Giuliana, Cervone, Silvestre, Devangelio, Eleonora, Lamacchia, Olga, Arena, Salvatore, Di Benedetto, Antonino, Frittitta, Lucia, Giordano, Carla, Piro, Salvatore, Rizzo, Manfredi, Chianetta, Roberta, Mannina, Carlo, Anichini, Roberto, Penno, Giuseppe, Solini, Anna, Fattor, Bruno, Bonora, Enzo, Cigolini, Massimo, Lapolla, Annunziata, Chilelli, Nino Cristiano, Poli, Maurizio, Simioni, Natalino, Frison, Vera, Vinci, Carmela, Fadini, G P, Solini, A, Manca, M L, Zatti, G, Karamouzis, I, Di Benedetto, A, Frittitta, L, and Avogaro, A, Giordano, C

Subjects
Male, Epidemiology, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Kidney, Type 2 diabete, Settore MED/13 - Endocrinologia, 0302 clinical medicine, Endocrinology, 80 and over, Medicine, Diabetic Nephropathies, 030212 general & internal medicine, Aged, 80 and over, education.field_of_study, General Medicine, Insulin resistance, Nephropathy, Protective, Diabetes and Metabolism, Phenotype, Lipotoxicity, Female, Type 2, Human, Glomerular Filtration Rate, medicine.medical_specialty, Population, Renal function, Internal Medicine, Diabetes Mellitus, Type 2, Humans, 03 medical and health sciences, Internal medicine, Diabetes mellitus, Diabetes Mellitus, education, Aged, business.industry, medicine.disease, Diabetic Nephropathie, business, Kidney disease
Abstract

AimsType 2 diabetes (T2D) accelerates the decline in glomerular function; however, some individuals do not develop chronic kidney disease despite advanced age and long-lasting T2D. We aimed to phenotype patients with T2D aged 80years or older who presented with a fully preserved kidney function.MethodsFrom an Italian population of 281,217 T2D outpatients, we collected data on demographics, anthropometrics, diabetes duration, HbA1c, fasting plasma glucose, lipids, liver enzymes, estimated glomerular filtration rate (eGFR), albumin excretion rate (AER), chronic complications, and medication use. We primarily compared patients with a fully preserved kidney function (eGFR>90ml/min/1.73m(2) and AER

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results